Sawai Pharmaceutical $1.1 billion acquisition of Upsher-Smith Laboratories' generic drug business

Overview:

• Japan's Sawai Pharmaceutical has acquired US-based Upsher-Smith Laboratories' generic drug business in a $1.1 billion deal.
• Sawai is funding the deal through loans and available cash.
• Torreya Partners and SMBC Nikko Securities acted as financial advisers for Sawai and JPMorgan Securities and BMO Capital Markets acted for Upsher-Smith.
• The transaction is expected to close by the end of June 2017.

Kurt Stumpo - Journalist